Baseline predictors of post-treatment diffusion capacity after neoadjuvant chemo-immunotherapy in non-small-cell lung cancer: development and external validation of a clinical prediction model

Clicks: 4
ID: 338634
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #145 of 148 articles by views in Interdisciplinary CardioVascular and Thoracic Surgery

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 148 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
OBJECTIVES: Routine repetition of pulmonary function tests (PFTs) following neoadjuvant chemo-immunotherapy is standard but may be redundant in selected patients. We aimed to develop and externally validate a multivariable model to predict post-treatment carbon monoxide lung diffusion capacity (DLCO), with the objective of identifying patients at low predicted risk of clinically important post-treatment impairment in whom selective omission of repeat testing could potentially be considered. METHODS: A predictive model was derived from 106 patients with locally advanced non-small cell lung cancer (NSCLC) undergoing neoadjuvant chemo-immunotherapy. Multivariable regression with backward stepwise elimination was used to test candidate predictors. The model was validated on an external cohort of 60 patients. Agreement was assessed using locally weighted scatterplot smoothing (Lowess) curves and misclassification rates relative to a clinically relevant threshold of DLCO<60%. RESULTS: The final model retained four independent predictors: Baseline DLCO (p < 0.001), Age (p < 0.001), Programmed death-ligand 1 (PD-L1) expression (p = 0.043), and Smoking status (p = 0.10). Applied to the external validation cohort (n = 60), the model demonstrated a median predicted DLCO of 66% (IQR 59-79) versus an observed DLCO of 73% (IQR 59-83), and Lowess curves indicated a stable relationship across the data range. The model correctly identified 100% of patients with an observed post-treatment DLCO<60% by using a predicted threshold of < 65%. All patients with a predicted DLCO>65% had an observed DLCO>60%. CONCLUSIONS: We developed and externally validated a clinical model that reliably predicts post-neoadjuvant DLCO. The model may help identify asymptomatic patients at low likelihood of a post-treatment DLCO <60% in whom repeat PFT assessment could potentially be omitted. Prospective validation is required before this approach can be recommended in routine clinical practice.
Reference Key
openalex_W7225230043 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Patrick Deniz Hurley, Guillermo Rodriguez Davila, David Gómez de Antonio, María Teresa Gómez-Hernández, Joshil Vinod Lodhia, Marcelo Jimenez, Marco Nardini, Nuria Maria Novoa, Peter Tcherveniakov, Elaine Teh, Alessandro Brunelli
Are you one of these authors? Claim your profile
Journal Interdisciplinary CardioVascular and Thoracic Surgery
Year 2026
DOI
10.1093/icvts/ivag292
URL
https://doi.org/10.1093/icvts/ivag292
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.